July 9, 2015 |
The U.S. Customs conversation is often the same for Kemal Malik, who carries a United Kingdom passport as a top executive for the German-based global giant Bayer AG. The agent will ask Malik what company he works for. Malik: "Bayer. " Agent: "Oh, the aspirin company. " "That's what we are known for, and that's great," Malik said in Philadelphia recently at the American Association for Cancer Research meeting. "But we want to be known for other stuff and we have that opportunity.
February 23, 2015 |
At Martin O'Riordan's cardiology practice in Darby and Springfield, it happens weekly. A 45- or 50-year-old patient mentions that her father had a heart attack at the same age. Worried that the same fate will befall her despite being in good health, she takes baby aspirin every day. O'Riordan's typical response: Please stop. Physicians have known for decades that daily, low-dose aspirin makes sense for patients who have had a heart attack or stroke, as it sharply reduces the chance of having a second one. But for people who have never had one of these cardiovascular "events," the thinking on aspirin is less clear, despite two recent large-scale studies.
September 15, 2014 |
The seven patients all had had successful surgery to prop open a blocked coronary artery with a stent. Yet more than five years later, all seven developed dangerous blood clots and came to Thomas Jefferson University Hospital with heart attacks. The common thread? All of them either had stopped taking aspirin, were actively smoking, or both, according to a new report by Jefferson physicians. Not a good idea, the doctors wrote in September's Journal of Invasive Cardiology.
April 20, 2013
Garret FitzGerald, chair of the pharmacology department at the University of Pennsylvania, has been awarded the 2013 Grand Prix Scientifique, considered the world's most prestigious honor for cardiovascular research. FitzGerald shares the prize with Carlo Patrono, chair of pharmacology at Catholic University in Rome, for their work showing that low-dose aspirin can help prevent cardiovascular disease. The prize, valued at 500,000 euros ($650,000), will be awarded under the presidency of the chancellor of the Institut de France and the president of the French Academy of Sciences on June 5. In a statement, FitzGerald said he was delighted to receive the prize and to share it with Patrono, "a special friend for more than 30 years.
January 29, 2013
If you're worried about the recent study linking aspirin use to an age-related disease that leads to blindness , specialists at Wills Eye Institute have some reassuring advice. The Australian study, published last week in JAMA Internal Medicine, found that taking aspirin at least once a week more than doubled the chance of macular degeneration, including the more damaging "wet" type, among 2,389 adults followed for 15 years. But the 15-year incidence was still relatively small - about 5.8 percent of regular aspirin users compared with 2.2 percent of nonusers.
December 18, 2012 |
One of the enduring tragedies of fair Ireland, beset by recurring economic woes, is that it loses many of its best and brightest, who, in search of opportunity, emigrate, most often to the United States. A sterling example of this brain drain is Garret FitzGerald, who was born in Dublin, and came here the first time at age 18 to take a summer job driving a Coca-Cola truck. Since then, he has risen fast and far. After earning his medical degree at University College in Dublin, FitzGerald eventually returned to the United States and during the 1980s ran the clinical pharmacology division at Vanderbilt University.
December 6, 2012 |
Bucking conventional wisdom, a University of Pennsylvania study concludes that natural resistance to the heart-protective effects of aspirin is rare, and questions the value of increasingly widely used screening tests for aspirin resistance. The study also found that coated aspirin pills, touted as being easier on the stomach, can throw off the tests, which measure how much aspirin reduces the formation of blood clots. "The incidence of true aspirin resistance is vanishingly small, and the idea of testing for it is seriously undermined by this study," said senior author Garret A. FitzGerald, an expert on blood clotting.
October 26, 2012 |
NEW YORK - Aspirin, one of the world's oldest and cheapest drugs, has shown remarkable promise in treating colon cancer in people with mutations in a gene that's thought to play a role in the disease. Among patients with the mutations, those who regularly took aspirin lived longer than those who didn't, a major study found. Five years after their cancers were diagnosed, 97 percent of the aspirin users were still alive versus 74 percent of those not taking the drug. Aspirin seemed to make no difference in patients who did not have the mutations.
May 28, 2012 |
The best way for a patient to understand what happens in a heart attack is not to have one at all, but to have the doctor simulate it on a computer. That is the idea behind new research at the University of Pennsylvania, in which scientists created computer models of the blood of three volunteers and correctly predicted their response to various anticlotting medications. In one case, they were able to determine that a donor's blood would have no response to aspirin, and indeed that person turned out to have a previously unknown genetic mutation that caused exactly that problem.